BioCardia (BCDA) vs Marker Therapeutics (MRKR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Marker Therapeutics (MRKR) has outperformed BioCardia (BCDA) over the past year, losing 12.0% versus a loss of 25.4%. Over five years, MRKR leads with a -94.0% price change compared with -97.6% for BCDA. BioCardia is the larger company by market cap ($16.0 million vs $15.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCDA | MRKR |
|---|---|---|
| Share price | $1.06 | $0.95 |
| Market cap | $16.05M | $15.84M |
| 1-day change | -2.75% | -8.65% |
| YTD return | -15.20% | -36.24% |
| 1-year return | -25.35% | -12.04% |
| 5-year return | -97.59% | -94.03% |
| EPS (TTM) | $-0.64 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.80 | $2.46 |
| 52-week low | $0.75 | $0.84 |
| Distance from 52-week high | -41.11% | -61.38% |
| Analyst consensus | none | none |
| Avg. price target upside | +1362.26% | +728.42% |
| Average volume | 282.05K | 64.80K |
| Shares outstanding | 15.14M | 16.67M |
| Employees | 17 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRKR has outperformed BCDA by 13.3 percentage points over the past year.
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Healthcare · Biotechnology · 17 employees
About Marker Therapeutics
MRKR stock →Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
Healthcare · Biotechnology · 5 employees
BCDA vs MRKR FAQ
Which is bigger, BioCardia or Marker Therapeutics?
BioCardia (BCDA) is larger, with a market capitalization of $16.05M compared with $15.84M for Marker Therapeutics (MRKR).
Which stock has performed better over the past year, BCDA or MRKR?
MRKR returned -12.04% over the past 12 months, compared with -25.35% for BCDA (price return, excluding dividends). Past performance does not predict future results.
Are BioCardia and Marker Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.